ATE381894T1 - Zubereitung zur vorbeugung und behandlung von gefässkrankheiten - Google Patents

Zubereitung zur vorbeugung und behandlung von gefässkrankheiten

Info

Publication number: ATE381894T1
Authority: AT; Austria
Prior art keywords: fraction; prevention; treatment; preparation; vascular diseases
Prior art date: 2000-05-08

Application number

AT01928256T

Other languages

English (en)

Inventor

Amanda Kiliaan

Robert Hageman

Original Assignee

Nutricia Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-08

Filing date

2001-05-08

Publication date

2008-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27074171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE381894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-08 Application filed by Nutricia Nv filed Critical Nutricia Nv

2008-01-15 Application granted granted Critical

2008-01-15 Publication of ATE381894T1 publication Critical patent/ATE381894T1/de

Links

230000002265 prevention Effects 0.000 title abstract 2
208000019553 vascular disease Diseases 0.000 title abstract 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
150000003904 phospholipids Chemical class 0.000 abstract 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
229930003779 Vitamin B12 Natural products 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229960000304 folic acid Drugs 0.000 abstract 1
235000019152 folic acid Nutrition 0.000 abstract 1
239000011724 folic acid Substances 0.000 abstract 1
210000003918 fraction a Anatomy 0.000 abstract 1
210000000540 fraction c Anatomy 0.000 abstract 1
235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
229910052749 magnesium Inorganic materials 0.000 abstract 1
235000001055 magnesium Nutrition 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
150000003905 phosphatidylinositols Chemical class 0.000 abstract 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 1
235000019163 vitamin B12 Nutrition 0.000 abstract 1
239000011715 vitamin B12 Substances 0.000 abstract 1
235000019158 vitamin B6 Nutrition 0.000 abstract 1
239000011726 vitamin B6 Substances 0.000 abstract 1
229940011671 vitamin b6 Drugs 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1
235000016804 zinc Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Nutrition Science (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Natural Medicines & Medicinal Plants (AREA)
Botany (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)

AT01928256T 2000-05-08 2001-05-08 Zubereitung zur vorbeugung und behandlung von gefässkrankheiten ATE381894T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US56638600A	2000-05-08	2000-05-08
US09/703,798 US7226916B1 (en)	2000-05-08	2000-11-02	Preparation for the prevention and/or treatment of vascular disorders

Publications (1)

Publication Number	Publication Date
ATE381894T1 true ATE381894T1 (de)	2008-01-15

Family

ID=27074171

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT01928256T ATE381894T1 (de)	2000-05-08	2001-05-08	Zubereitung zur vorbeugung und behandlung von gefässkrankheiten
AT07120681T ATE431133T1 (de)	2000-05-08	2001-05-08	Präparat zur verhinderung und/oder behandlung von demenz syndromen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT07120681T ATE431133T1 (de)	2000-05-08	2001-05-08	Präparat zur verhinderung und/oder behandlung von demenz syndromen

Country Status (13)

Country	Link
US (5)	US7226916B1 (de)
EP (5)	EP2316426B1 (de)
CN (1)	CN1245984C (de)
AT (2)	ATE381894T1 (de)
AU (1)	AU2001255114A1 (de)
CA (1)	CA2408032C (de)
CY (3)	CY1107237T1 (de)
DE (2)	DE60132081T2 (de)
DK (3)	DK2070519T6 (de)
ES (3)	ES2298232T3 (de)
HK (1)	HK1052439B (de)
PT (3)	PT2070519E (de)
WO (1)	WO2001084961A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69904257T2 (de) *	1999-01-20	2003-04-17	N.V. Nutricia, Zoetermeer	Säuglingsnährpräparat
US7226916B1 (en)	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) *	2000-05-08	2007-04-24	N.V. Nutricia	Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
JP2003048831A (ja)	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20040234544A1 (en) *	2001-08-09	2004-11-25	Ralf Jager	Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
NL1019368C2 (nl)	2001-11-14	2003-05-20	Nutricia Nv	Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en)	2002-03-05	2014-05-20	Pronova Biopharma Norge As	Use of EPA and DHA in secondary prevention
GB0210212D0 (en) *	2002-05-03	2002-06-12	Univ Southampton	Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
DE10250727B4 (de) *	2002-04-19	2008-07-10	Cargill, Incorporated, Wayzata	Matrix mit einer bioaktiven Phospholipid-haltigen Komponente
JP4599604B2 (ja) *	2002-04-19	2010-12-15	カーギルテクスチュアライジングソリューションズドイチュラントゲゼルシャフトミットベシュレクテルハフツングウントコンパニーコマンディートゲゼルシャフト	生体活性のリン脂質含有成分を含有するマトリックス
DE10217555A1 (de) *	2002-04-19	2004-02-19	Degussa Bioactives Deutschland Gmbh	Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
DE10217557A1 (de) *	2002-04-19	2003-11-06	Degussa Bioactives Gmbh	Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix
EP1501493B1 (de) *	2002-05-03	2009-10-07	Pronova BioPharma Norge AS	Verwendung von epa and dha zur sekundären prevention von schlaganfällen
CN100469361C (zh)	2002-06-19	2009-03-18	纽迪希亚公司	治疗或预防哺乳动物遭受代谢作用压力时的分解代谢或刺激性合成代谢的方法及组合物
EP1388295A1 (de) *	2002-08-07	2004-02-11	Nestec S.A.	DHA-enthaltendes Nahrungsmittel auf Getreidebasis
FR2847472B1 (fr) *	2002-11-22	2006-08-11	Synergia	Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires
DK1589834T3 (da) *	2003-02-05	2007-06-18	Nutricia Nv	Enteral komposition til forebyggelse og/eller behandling af sepsis
JP2006523642A (ja) *	2003-04-17	2006-10-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	妊娠女性用のマルチ−ビタミンおよびミネラル補助剤
US8703209B2 (en)	2003-06-17	2014-04-22	Edward Larry McCleary	Composition and method for modulating hydrogen ion physiology
JP4870430B2 (ja) *	2003-06-20	2012-02-08	持田製薬株式会社	下肢静脈瘤予防・治療用組成物
AU2004257756A1 (en) *	2003-07-10	2005-01-27	Carl A. Forest	Foods, beverages, condiments, spices and salad dressings with specialized supplements
US8017160B2 (en) *	2003-08-15	2011-09-13	Russell Jaffe	Enhancement of magnesium uptake in mammals
DE10340740A1 (de) *	2003-09-04	2005-03-31	Degussa Food Ingredients Gmbh	Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis
IL158139A0 (en) *	2003-09-25	2004-09-27	Enzymotec Ltd	Stabilized formulations of phosphatidyl serine
US8052992B2 (en)	2003-10-22	2011-11-08	Enzymotec Ltd.	Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US7935365B2 (en)	2003-10-22	2011-05-03	Enzymotec, Ltd.	Glycerophospholipids for the improvement of cognitive functions
US20050130937A1 (en)	2003-10-22	2005-06-16	Enzymotec Ltd.	Lipids containing omega-3 and omega-6 fatty acids
JP4993852B2 (ja)	2004-09-17	2012-08-08	サントリーホールディングス株式会社	ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
EP1645276A1 (de) *	2004-10-08	2006-04-12	Wageningen Centre for Food Sciences	Behandlung von neurodegenerativen Erkrankungen
EP1845999A4 (de) *	2005-01-24	2010-09-22	Pronova Biocare As	Verwendung einer fettsäurezusammensetzung mit dha zur herstellung eines medizinischen produkts oder eines nahrungsmittels zur behandlung von krankheiten in verbindung mit amyloidose
CA2645645C (en) *	2005-05-23	2015-07-14	Massachusetts Institute Of Technology	Compositions containing pufa and methods of use thereof
JP5967855B2 (ja)	2005-06-30	2016-08-10	サントリーホールディングス株式会社	日中活動量の低下および／又はうつ症状の改善作用を有する組成物
WO2007045407A2 (en) *	2005-10-18	2007-04-26	Artmed S.R.L.	Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma
USRE46372E1 (en)	2006-01-19	2017-04-25	The Regents Of The Univerity Of Michigan	Method for treating hearing loss
US10238599B2 (en)	2006-01-19	2019-03-26	The Regents Of The University Of Michigan	Composition and method for treating congenital cytomegalovirus induced hearing loss
US7951845B2 (en)	2006-01-19	2011-05-31	The Regents Of The University Of Michigan	Composition and method of treating hearing loss
US9919008B2 (en)	2006-01-19	2018-03-20	The Regents Of The University Of Michigan	Method for treating age-related hearing loss (ARHL)
US8927528B2 (en)	2006-01-19	2015-01-06	The Regents Of The University Of Michigan	Composition for treating hearing loss
US9889156B2 (en)	2006-01-19	2018-02-13	The Regents Of The University Of Michigan	Method for treating noise-induced hearing loss (NIHL)
US9770433B2 (en)	2006-01-19	2017-09-26	The Regents Of The University Of Michigan	Composition and method for treating tinnitus
US8338397B2 (en)	2006-01-19	2012-12-25	The Regents Of The University Of Michigan	Composition and method of treating side effects from antibiotic treatment
US8871808B2 (en)	2006-06-22	2014-10-28	Ben-Gurion University Of The Negev Research And Development Authority Et Al.	Over-production of dihomo linolenic acid by a mutant strain of Parietochloris incisa
PL2046312T3 (pl) *	2006-07-14	2021-02-08	Kaydence Pharma As	Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2
KR101578498B1 (ko)	2006-12-28	2015-12-18	산토리 홀딩스 가부시키가이샤	신경 재생제
WO2009002145A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Lipid composition for improving function of brain functioning
WO2009002146A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Supporting activities of daily living
WO2009002166A1 (en)	2007-06-26	2008-12-31	N.V. Nutricia	Improving memory in subjects with mini-mental state examination of 24-26
WO2009002148A1 (en)	2007-06-27	2008-12-31	N.V. Nutricia	Food composition for prodromal dementia patients
WO2009022323A1 (en) *	2007-08-13	2009-02-19	Ben-Gurion University Of The Negev Research And Development Authority	Over-production of dihomo gamma linolenic acid by a mutant strain of parietochloris incisa
DE102007042557A1 (de) *	2007-09-07	2009-03-19	Membramed Gmbh	Neuartige Formulierung von Phospholipiden
ES2748136T3 (es)	2007-10-15	2020-03-13	United Animal Health Inc	Método para aumentar el rendimiento de las crías
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009070589A1 (en) *	2007-11-30	2009-06-04	Jbs United, Inc.	Method and composition for treating pulmonary hemorrhage
BRPI0822111B8 (pt)	2007-12-20	2021-05-25	Nutricia Nv	composição líquida, e, uso de uma composição líquida
US9034399B2 (en) *	2008-01-03	2015-05-19	Melaleuca, Inc.	Dietary compositions for promoting brain health
US20110052556A1 (en)	2008-02-29	2011-03-03	Biolab Sanus Farmaceutical Ltda	Pharmaceutical composition comprising racetam and carnitine and process for its preparation
EP2172203A1 (de) *	2008-09-17	2010-04-07	Giuliani S.P.A.	Pharmazeutisches Zusammensetzung zur Behandlung von Magen-Darm-Reizungsstörungen
CA2777233A1 (en) *	2008-10-13	2010-04-22	Pregnant Princess & Co. Ltd.	Compositions and methods for treating varicose veins
CN102438468B (zh) *	2009-04-17	2014-06-04	纳塔克制药有限公司	富含低含量植烷酸的ω-3脂肪酸的组合物
WO2011066471A1 (en)	2009-11-25	2011-06-03	Loma Linda University Medical Center	Chitosan-based hemostatic textile
AU2011315537A1 (en) *	2010-10-12	2013-05-02	Vifor Sa	Novel omega-3 and omega-6 fatty acid compositions and uses thereof
US9481861B2 (en)	2011-07-12	2016-11-01	Foodchek Systems, Inc.	Culture medium, method for culturing Salmonella and E. coli and method for detecting Salmonella and E. coli
RU2505290C2 (ru) *	2011-10-31	2014-01-27	Общество С Ограниченной Ответственностью "Консорциум-Пик"	Фармацевтическая композиция, обладающая свойством снижения эндотелиальной дисфункции при заболеваниях сердечно-сосудистой системы
WO2013138368A1 (en) *	2012-03-12	2013-09-19	Loma Linda University Medical Center	Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
EP3043658B1 (de)	2013-08-29	2019-11-20	Abbott Laboratories	Nahrungszusammensetzung enthaltend fettlösliche verbindungen mit verbesserten löslichkeit und bioverfügbarkeit
CN103432156A (zh) *	2013-08-30	2013-12-11	深圳奥萨医药有限公司	ω-3脂肪酸和B族维生素的药物组合物及其用途
GB201405033D0 (en)	2014-03-20	2014-05-07	Isis Innovation	Combination therapy
US9259357B2 (en)	2014-04-16	2016-02-16	Loma Linda University	Composition, preparation, and use of chitosan shards for biomedical applications
DE202014102551U1 (de) *	2014-05-30	2015-02-26	Orthomol Pharmazeutische Vertriebs Gmbh	Diätetische Zubereitung in Form eines Riegels
US10183044B2 (en) *	2015-05-15	2019-01-22	P Tech, Llc	Systems and methods for thrombosis prevention
ES2795836T3 (es) *	2015-07-29	2020-11-24	Abbott Lab	Productos nutricionales con biodisponibilidad y solubilidad lipófila mejoradas en una forma fácil de mezclar
CN105079009B (zh)	2015-08-25	2018-05-01	厦门金达威生物科技有限公司	预防和/或治疗心脑血管疾病的组合物
CN107252089A (zh) *	2017-04-05	2017-10-17	吉林省润生特膳食品科技开发有限公司	一种山楂桃仁山药粉及其制备方法
AU2018390261B2 (en)	2017-12-21	2023-03-16	Nippon Zoki Pharmaceutical Co., Ltd.	Agent for treatment of nervous system disease
CN110404049A (zh) *	2019-07-23	2019-11-05	张明	通过雾化吸入防治心脑血管病和老年痴呆的组合物及应用
FR3099339B1 (fr) *	2019-08-01	2022-06-17	Specialites Pet Food	Hydrolysat protéique issu de poissons bleus
CN112843072B (zh) *	2021-01-12	2026-07-10	山东省科学院生物研究所	磷脂在调控血管生成方面的应用
CN113456640A (zh) *	2021-08-26	2021-10-01	烟台大学	石杉碱甲在心肌缺血损伤预防中的应用
EP4748443A3 (de)	2021-09-17	2026-08-12	N.V. Nutricia	Feste zusammensetzung als ernährungszusammensetzung oder ergänzungsstoff für tiere, die an gehirnbedingten erkrankungen, abbau oder erkrankungen leiden
IT202200010583A1 (it) *	2022-05-23	2023-11-23	Neilos S R L	“Composizione nutraceutica o farmaceutica per l’infertilità maschile”
GB202209414D0 (en) *	2022-06-27	2022-08-10	Aker Biomarine Antarctic As	Uses for phospholipid compositions

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2824362A1 (de)	1978-06-01	1979-12-13	Josef Dipl Chem Dr Rer N Klosa	Pharmazeutisches praeparat mit l-tryptophan
IT1212900B (it) *	1983-11-17	1989-11-30	Valle Francesco Della	Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna
AU594066B2 (en)	1985-07-26	1990-03-01	Yeda Research And Development Co. Ltd.	A special lipid mixture for membrane fluidization
US4897380A (en)	1985-08-30	1990-01-30	Pollack Robert L	Method and composition for relieving dietary-related disorders
US5177082A (en) *	1985-11-05	1993-01-05	Yu Chao Mei	Huperzines and analogs
GB8601915D0 (en) *	1986-01-27	1986-03-05	Efamol Ltd	Pharmaceutical compositions
JPS63208524A (ja)	1987-02-25	1988-08-30	Nippon Oil & Fats Co Ltd	睡眠リズム改善剤
IL86423A0 (en)	1987-05-19	1988-11-15	Baylor College Medicine	Pharmaceutical compositions for the treatment of alzheimer's disease
WO1989002737A1 (en)	1987-09-30	1989-04-06	University Of Florida	Treatment of hypertension by chronic administration of l-tryptophan or l-5-hydroxytryptophan
US4837219A (en) *	1987-11-05	1989-06-06	Jeffrey Hutterer	Medication for Alzheimer's disease
US5004615A (en) *	1988-04-27	1991-04-02	Bionix Corporation	Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
JP2732109B2 (ja) *	1989-02-10	1998-03-25	正樹今川	痴呆治療剤
JP2909508B2 (ja) *	1989-02-14	1999-06-23	マルハ株式会社	オキアミリン脂質の分取方法
US6294520B1 (en)	1989-03-27	2001-09-25	Albert T. Naito	Material for passage through the blood-brain barrier
JPH02302732A (ja)	1989-05-18	1990-12-14	Seiko Epson Corp	液晶表示装置
US5401730A (en) *	1990-07-06	1995-03-28	The Hope Heart Institute	Method for reducing platelet aggregation
US5077069A (en)	1991-01-07	1991-12-31	Kabi Pharmacia Ab	Composition of natural antioxidants for the stabilization of polyunsaturated oils
US5108767A (en)	1991-06-10	1992-04-28	Abbott Laboratories	Liquid nutritional product for persons receiving renal dialysis
DE4309217A1 (de) *	1992-01-18	1994-07-28	Margarethe Rabien	Kombinationspräparat Pantothensäure bzw. Dexpanthen + alpha-Liponesäure + Vitamin E (Muskeldystrophie, Polyneuropathie, Muskelatrophie Atoxie, neue Indikation (alpha-Liponsäure + Pantothensäure) Alzheimersche Krankheit
US5234702A (en)	1992-03-19	1993-08-10	Abbott Laboratories	Antioxidant system for powdered nutritional products
US5223285A (en)	1992-03-31	1993-06-29	Abbott Laboratories	Nutritional product for pulmonary patients
US5308832A (en)	1992-07-27	1994-05-03	Abbott Laboratories	Nutritional product for persons having a neurological injury
JPH0717855A (ja)	1992-09-02	1995-01-20	Maruha Corp	脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
DE4304394A1 (en)	1993-02-13	1993-09-02	Fresenius Ag	Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
WO1994027628A1 (en)	1993-05-28	1994-12-08	Abbott Laboratories	Enteral nutritional product
WO1995015750A1 (en) *	1993-12-10	1995-06-15	Hashim Sami A	Reducing likelihood of vascular disorders in susceptible patients
FR2714574B1 (fr)	1993-12-31	1996-03-15	Inst Rech Biolog Sa	Nouveaux suppléments alimentaires pour la nutrition des très jeunes enfants.
JPH07224142A (ja)	1994-02-08	1995-08-22	Dai Ichi Kogyo Seiyaku Co Ltd	エポキシ樹脂及びエポキシ樹脂組成物
DE69525150T2 (de)	1994-04-01	2002-09-05	Abbott Laboratories, Abbott Park	Nahrungsprodukt zur behandlung der ulzerativen kolitis sowie verwendung desselben
CA2150741A1 (en)	1994-06-17	1995-12-18	Susan Trimbo	Pediatric lipid emulsion
JP3053537B2 (ja)	1994-11-08	2000-06-19	株式会社ヤクルト本社	脳機能改善剤
GB9423625D0 (en) *	1994-11-23	1995-01-11	Scotia Holdings Plc	Fortified fruit juice
US5589468A (en)	1995-01-13	1996-12-31	Clintec Nutrition Co.	Method for providing nutrition to elderly patients
EP0726073A3 (de) *	1995-02-10	1998-07-08	Eduardo Samuel Bleiweiss	Pharmazeutische Zusammensetzungen, welche mindestens eine von Haloperidol, Imipramine oder Trifluorperazine enthalten
JPH08252856A (ja)	1995-03-16	1996-10-01	Asahi Glass Co Ltd	樹脂枠体付き窓用板状体の製造装置
JPH0954212A (ja) *	1995-08-11	1997-02-25	Sharp Corp	位相差フィルム及びその製造方法、並びに液晶表示素子
JP3791951B2 (ja)	1995-11-08	2006-06-28	株式会社ヤクルト本社	多価不飽和脂肪酸含有ホスファチジルセリンを含む油脂組成物の製造方法
IT1277953B1 (it) *	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
GB9606736D0 (en) *	1996-02-19	1996-06-05	Shire International Licensing	Therapeutic method
AU2583397A (en)	1996-04-10	1997-10-29	Chronorx, Llc	Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
WO1997039759A2 (en)	1996-04-24	1997-10-30	Brigham And Women's Hospital	Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
US6077828A (en)	1996-04-25	2000-06-20	Abbott Laboratories	Method for the prevention and treatment of cachexia and anorexia
JP3664814B2 (ja) *	1996-06-26	2005-06-29	旭化成ケミカルズ株式会社	血中脂質改善剤及び食品添加剤
US6008221A (en) *	1996-11-06	1999-12-28	Bristol-Myers Squibb Company	Method for treating Alzheimer's disease with folic acid
JPH10140919A (ja)	1996-11-11	1998-05-26	Mika Oosawa	建物空間内の間仕切り構造
ATE221324T1 (de) *	1996-11-20	2002-08-15	Nutricia Nv	Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
JPH10165119A (ja) *	1996-12-10	1998-06-23	Seijiro Yanai	イチョウ葉エキス添加強化米及びその製造方法
US6013273A (en)	1997-01-27	2000-01-11	Novartis Nutrition Ag	Treatment of endotoxic shock
GB9701675D0 (en)	1997-01-28	1997-03-19	Bridgeman Keith	Composition for the treatment of parkinson's disease
EP1021177A4 (de)	1997-02-04	2002-05-15	John V Kosbab	Zusammensetzungen und verfahren zur verhütung und behandlung von vaskulär-degeneratieve krankheiten
US5843469A (en) *	1997-04-11	1998-12-01	Mcentee; William J.	Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system
US6344482B1 (en)	1997-04-23	2002-02-05	Andrew L. Stoll	Omega-3 fatty acids in the treatment of bipolar disorder
US5820867A (en)	1997-04-24	1998-10-13	Bewicke; Calverly M.	General anti-depressant composition for dietary supplement
AU7222598A (en)	1997-04-29	1998-11-24	Scotia Holdings Plc	Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
FR2762993B1 (fr)	1997-05-06	1999-08-13	Inst Rech Biolog Sa	Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
EP0891719A1 (de)	1997-07-14	1999-01-20	N.V. Nutricia	Narungszusammensetzungen mit Gehalt an Methionin
GB9715444D0 (en)	1997-07-22	1997-09-24	Scotia Holdings Plc	Therapeutic and dietary compositions
AU8925998A (en)	1997-09-03	1999-03-22	Macro Hi-Tech Jv, Ltd.	Huperzine a derivatives
US6537969B1 (en)	1997-10-24	2003-03-25	John P. Blass	Nutritional supplement for cerebral metabolic insufficiencies
US5922704A (en) *	1997-12-24	1999-07-13	Feeling Fine Company Llc	Optimal nutritional supplement for men
FR2773484B1 (fr) *	1998-01-09	2001-03-30	Pierre Moreau	Nouvelles compositions a effet synergique entre micronutriments et substances d'origine vivante
CN1288383A (zh)	1998-01-13	2001-03-21	雷克索尔日落公司	贯叶金丝桃和甲基供体组合物及其用途
WO1999037155A1 (en)	1998-01-27	1999-07-29	Nutramax Laboratories, Inc.	Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
GB9808579D0 (en)	1998-04-22	1998-06-24	Novartis Nutrition Ag	Improvements in or relating to organic compounds
HUP0101890A2 (hu)	1998-05-04	2001-10-28	Andreas Johannes Kesel	Monomer, oligomer és polimer knoevenagel-kondenzációs termékek
CN1235770A (zh) *	1998-05-15	1999-11-24	武汉华凯保健品开发有限公司	银杏茶
EP1085886A1 (de)	1998-06-11	2001-03-28	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Schutz von neuronen gegen ischämia
IT1299195B1 (it)	1998-06-25	2000-02-29	Sigma Tau Healthscience Spa	Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
CA2340223A1 (en)	1998-08-12	2000-02-24	Morinaga Milk Industry Co., Ltd.	Nutritional compositions for preventing or treating hyperlipoproteinemia
JP2000148134A (ja)	1998-11-13	2000-05-26	Seiko Epson Corp	画像表示方法および画像処理装置
FR2788437B1 (fr)	1999-01-14	2006-08-11	Inst Rech Biolog Sa	Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
US6120814A (en) *	1999-02-22	2000-09-19	Nature's One, Inc.	Organic nutritional formula
GB9916536D0 (en)	1999-07-14	1999-09-15	Scarista Limited	Nutritional or pharmaceutical compositions
US7208180B2 (en)	2000-05-08	2007-04-24	N.V. Nutricia	Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en)	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
EP2632360A4 (de)	2010-10-29	2014-05-21	Bard Inc C R	Bioimpedanz-gestützte platzierung einer medizinischen vorrichtung

2000
- 2000-11-02 US US09/703,798 patent/US7226916B1/en not_active Expired - Lifetime
2001
- 2001-05-08 ES ES01928256T patent/ES2298232T3/es not_active Expired - Lifetime
- 2001-05-08 EP EP10186282.9A patent/EP2316426B1/de not_active Revoked
- 2001-05-08 HK HK03104859.9A patent/HK1052439B/en unknown
- 2001-05-08 EP EP01928256A patent/EP1282365B1/de not_active Revoked
- 2001-05-08 DK DK09156648.9T patent/DK2070519T6/en active
- 2001-05-08 PT PT09156648T patent/PT2070519E/pt unknown
- 2001-05-08 EP EP09156648.9A patent/EP2070519B3/de not_active Expired - Lifetime
- 2001-05-08 CN CNB018124615A patent/CN1245984C/zh not_active Expired - Lifetime
- 2001-05-08 ES ES07120681T patent/ES2326928T3/es not_active Expired - Lifetime
- 2001-05-08 DE DE60132081T patent/DE60132081T2/de not_active Expired - Lifetime
- 2001-05-08 DK DK01928256T patent/DK1282365T3/da active
- 2001-05-08 WO PCT/NL2001/000347 patent/WO2001084961A2/en not_active Ceased
- 2001-05-08 DK DK07120681T patent/DK1911442T3/da active
- 2001-05-08 AU AU2001255114A patent/AU2001255114A1/en not_active Abandoned
- 2001-05-08 DE DE60138742T patent/DE60138742D1/de not_active Expired - Lifetime
- 2001-05-08 PT PT01928256T patent/PT1282365E/pt unknown
- 2001-05-08 AT AT01928256T patent/ATE381894T1/de active
- 2001-05-08 EP EP07120681A patent/EP1911442B1/de not_active Revoked
- 2001-05-08 CA CA2408032A patent/CA2408032C/en not_active Expired - Lifetime
- 2001-05-08 PT PT07120681T patent/PT1911442E/pt unknown
- 2001-05-08 ES ES09156648T patent/ES2533362T7/es active Active
- 2001-05-08 EP EP20100186257 patent/EP2292210A1/de not_active Withdrawn
- 2001-05-08 AT AT07120681T patent/ATE431133T1/de active
2007
- 2007-04-27 US US11/741,547 patent/US7560447B2/en not_active Expired - Fee Related
2008
- 2008-03-11 CY CY20081100275T patent/CY1107237T1/el unknown
- 2008-04-14 US US12/102,754 patent/US7772217B2/en not_active Expired - Fee Related
2009
- 2009-07-21 CY CY20091100779T patent/CY1109248T1/el unknown
2010
- 2010-08-09 US US12/853,001 patent/US8377912B2/en not_active Expired - Fee Related
2013
- 2013-02-14 US US13/767,730 patent/US8865687B2/en not_active Expired - Fee Related
2015
- 2015-03-24 CY CY20151100298T patent/CY1116212T1/el unknown

Also Published As

Publication number	Publication date
US7772217B2 (en)	2010-08-10
DE60138742D1 (de)	2009-06-25
ATE431133T1 (de)	2009-05-15
EP1911442A2 (de)	2008-04-16
PT2070519E (pt)	2015-03-26
HK1052439B (en)	2008-02-29
US7560447B2 (en)	2009-07-14
ES2533362T3 (es)	2015-04-09
CN1440240A (zh)	2003-09-03
ES2298232T3 (es)	2008-05-16
CY1107237T1 (el)	2012-11-21
DK2070519T3 (da)	2015-03-30
EP1911442B1 (de)	2009-05-13
EP2292210A1 (de)	2011-03-09
US20100303784A1 (en)	2010-12-02
EP1282365A2 (de)	2003-02-12
EP2070519A1 (de)	2009-06-17
US8865687B2 (en)	2014-10-21
DE60132081D1 (de)	2008-02-07
EP1911442A3 (de)	2008-05-21
ES2533362T7 (es)	2019-02-04
WO2001084961A2 (en)	2001-11-15
HK1052439A1 (en)	2003-09-19
EP2316426A1 (de)	2011-05-04
CY1116212T1 (el)	2017-02-08
ES2326928T3 (es)	2009-10-21
CN1245984C (zh)	2006-03-22
PT1911442E (pt)	2009-09-01
AU2001255114A1 (en)	2001-11-20
DK1911442T3 (da)	2009-06-08
PT1282365E (pt)	2008-03-24
EP1282365B1 (de)	2007-12-26
US20070202194A1 (en)	2007-08-30
US20130157978A1 (en)	2013-06-20
US7226916B1 (en)	2007-06-05
EP2070519B1 (de)	2014-12-24
WO2001084961A3 (en)	2002-08-15
DK2070519T6 (en)	2018-11-19
DE60132081T2 (de)	2008-12-18
DK1282365T3 (da)	2008-03-31
CY1109248T1 (el)	2014-07-02
CA2408032C (en)	2012-08-21
US8377912B2 (en)	2013-02-19
EP2070519B3 (de)	2018-08-22
CA2408032A1 (en)	2001-11-15
EP2316426B1 (de)	2016-11-30
US20080193561A1 (en)	2008-08-14

Legal Events

Date

Code

Title

Description

2008-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1282365

Country of ref document: EP

Publication	Publication Date	Title
DE60132081D1 (de)	2008-02-07	ZUBEREITUNG ZUR VORBEUGUNG UND BEHANDLUNG VON GEFÄßKRANKHEITEN
DE60135319D1 (de)	2008-09-25	Präparation zur Vorbeugung und/oder Behandlung von vaskulären Erkrankungen und dazugehörigen sekundären Erkrankungen
BRPI0813320A2 (pt)	2015-01-06	Fração lipídica, e, produto farmacêutico ou nutricional
CY1110353T1 (el)	2015-04-29	Ανοσορρυθμιστικοι ολιγοσακχαριτες
ATE417610T1 (de)	2009-01-15	Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
RU2013135311A (ru)	2015-02-10	Комбинация компонентов для профилактики и лечения немощности
DK1411960T3 (da)	2006-07-24	Födevareprodukt af beriget risklid til fremme af hjerte-kar-sundhed
EP1339429A4 (de)	2007-03-14	Zusammensetzung enthaltend statine und calcium für verbesserte kardiovaskuläre gesundheit
ES2173673T3 (es)	2002-10-16	Mezcla grasa y agentes dieteticos o farmaceuticos que las contienen.
CN106535881A (zh)	2017-03-22	用于评估和治疗或预防受损的血浆极性脂质水平的方法
DE602004019884D1 (de)	2009-04-23	Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate
DK1638417T3 (en)	2019-01-28	COMBINATIONS OF VASO PROTECTIVE AGENTS AND FORMS CONTAINING THESE
ATE444745T1 (de)	2009-10-15	Verwendung von epa and dha zur sekundären prevention von schlaganfällen
WO2002043662A3 (en)	2003-01-23	Dietary composition containing conjugated linoleic acid and calcium for improved health
US10632093B2 (en)	2020-04-28	Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients
BR0307021A (pt)	2004-11-03	Uso de alquilfosfocolinas no tratamento preventivo de doenças de protozoários
EP3364961A1 (de)	2018-08-29	Verfahren zur verbesserung des gleichgewichtssinns bei gesunden personen und nahrungszusammensetzung
HK30065426A2 (en)	2022-07-22	Compositions and method for maintaining/improving liver and kidney health
ES2170654B1 (es)	2003-06-16	Perfeccionamientos introducidos en el objeto de la patente p9900757, por un procedimiento para la obtencion de gammaglobulinas de origen animal y aplicaciones correspondientes.